Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Ofran
Yishay
Y
Avivi
Irit
I
Gesundheit
Benjamin
B
Or
Reuven
R
Rowe
Jacob M
JM
Zuckerman
Tsila
T
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced*; D013577:Syndrome
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide